BOARD OF DIRECTORS
James Huang, Chairman
Mr. Huang has been Chairman of the Windtree Board of Directors since January 2019. He is currently a founding and Managing Partner to Panacea Venture. Panacea Venture is a venture capital firm that invests in early and growth stage healthcare and life sciences companies worldwide. Since 2011, Mr. Huang has served as a Managing Partner of Kleiner Perkins Caufield & Byers (KPCB) – China, focusing on the firm’s life sciences practice. Mr. Huang has made more than 15 investments in China since 2007. Prior to joining KPCB China, Mr. Huang was a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments.
Prior to joining Vivo in 2007, Mr. Huang was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, Mr. Huang also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). Mr. Huang is Chairman of Board at Kindstar Global, JHL Biotech and XW Laboratory and Director at ChiralQuest, Zenesis, and CASI Pharmaceuticals.
Mr. Huang received an M.B.A. from the Stanford Graduate School of Business in 1992 and a B.S. degree in chemical engineering from the University of California, Berkeley.
Craig Fraser joined Windtree in February of 2016 as President and Chief Executive Officer. He was also appointed to serve as a member of the Board of Directors in February 2016.
Mr. Fraser brings over 28 years of experience as a leader in both product development and commercial operations, and in building biopharmaceutical and device businesses for both startups and larger companies. Prior to joining the company, he held executive positions at several biopharmaceutical companies, including as Chief Operating Officer at Aegerion Pharmaceuticals, Vice President of Global Disease Areas at Pfizer, Vice President and Global Business Manager at Wyeth, and Vice President of Sales & Marketing and Commercial Operations at Johnson & Johnson / Centocor. Mr. Fraser is a veteran of both the U.S. Marine Corps and the U.S. Army.
Mr. Fraser received his B.S. degree from Slippery Rock University of Pennsylvania.
Daniel E. Geffken
Daniel Geffken has served as a member of the Windtree Board of Directors since April 2019. He serves as Chairman of the Board’s Audit Committee and is a member of the Compensation Committee. Mr. Geffken brings more than 30 years of financial management experience to the board, ranging from start-ups to publicly traded companies with over $1 billion market capitalizations. Since 2011, Mr. Geffken has been serving as the Founding Managing Partner of Danforth Advisors, a leading financial and strategy consulting firm to the life sciences industry. He has also served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Mr. Geffken has served on the Board of Directors of Elicio Bio, Alcobra Ltd. and Arcturus Inc., after its merger with Alcobra. Since 2013, he has assisted in ten initial public offering filings. Over the course of his career, he has assisted in raising more than $1 billion in equity and debt securities for life science companies.
Daniel holds a BS from The Wharton School, University of Pennsylvania, and an MBA from Harvard Business School.
John R. Leone
John R. Leone has served as a member of the Windtree Board of Directors since November 2012 and served as Chairman from 2013 through 2018. He serves as Chairman of the Nomination and Governance Committee and is a member of the Audit Committee. With over 30 years of experience, Mr. Leone has built an outstanding track record in pharmaceutical operations, commercial portfolio management, and financing life science companies. Mr. Leone’s commercial experience includes significant domestic and international executive management roles and direct responsibility for the commercial launch of numerous pharmaceutical products.
Mr. Leone has been a partner at Visium Asset Management LLC, an investment platform focused on health-care royalties and related revenues, since May 2013. Prior to joining Visium, Mr. Leone was a partner at Paul Capital Healthcare, a private equity firm that manages one of the largest dedicated global health-care funds. Previously, Mr. Leone served as President and Chief Executive Officer at Cambrex Corporation and as Senior Vice President and Chief Operating Officer of U.S. commercial operations at Aventis Pharmaceuticals. While at Aventis, he was responsible for all commercial business units, including oncology, metabolism, cardiovascular, dermatology, respiratory and anti-infective. Mr. Leone also served on the Board of Directors at ViroPharma Incorporated until its acquisition in March 2014.
Mr. Leone received his B.S. degree in Engineering from the U.S. Military Academy at West Point and his MBA from the University of Colorado.
Joseph M. Mahady
Joseph M. Mahady has served as a member of the Windtree Board of Directors since January 2013. He serves as Chairman of the Board’s Compensation Committee and a member of the Audit Committee. Mr. Mahady has extensive strategic and operational experience in the biopharmaceutical industry, and broad international commercial experience, having served in a direct leadership role in more than 30 product launches. He has a successful record of developing profitable businesses based on transformational technologies in both the U.S. and international markets.
Mr. Mahady held significant leadership positions during his 30-year career with Wyeth Corporation, including President of Wyeth Pharmaceuticals and Senior Vice President of Wyeth Corporation, with responsibility for directing the worldwide operations of Wyeth’s $20 billion global pharmaceutical business. He retired from Wyeth in 2009. Since his retirement Mr. Mahady served as a director on the boards of Albemarle, EKR Therapeutics and Strongbridge Biopharma and as Chairman of Lumara Health (formerly KV Pharmaceuticals).
Mr. Mahady received his B.S. degree in Pharmacy from St. John’s University College of Pharmacy and his MBA in Pharmaceutical Studies from Fairleigh Dickinson University.
Bruce A. Peacock
Bruce A. Peacock has served as a member of the Windtree Board of Directors since September 2010 and is a member of the board’s Nomination and Governance Committee. Mr. Peacock brings extensive biotech and pharmaceutical experience to the board, including financial expertise in debt, equity capital and alliance transactions. He also has significant experience in drug development, having led the effort to gain regulatory approval for several drug candidates in the United States and in other major markets worldwide. Mr. Peacock also has had responsibility for marketing, commercial and manufacturing operations.
Mr. Peacock has served as Chief Financial and Business Officer of Ophthotech Corporation, having served as Chief Business Officer since 2010. Previously, he served as President and Chief Executive Officer of Alba Therapeutics; Chief Executive Officer and Director of the Little Clinic, a medical care services company; President and Chief Executive officer and a Director of Adolor Corporation, a publicly-held biotechnology company; President, Chief Executive Officer and a Director of Orthovita Inc., a publicly-held orthopedic biomaterials company; Executive Vice President, Chief Operating Officer and a Director of Cephalon Inc.; and Chief Financial Officer of Centocor Inc.
Mr. Peacock has served as a director on the boards Ocular Therapeutix, Applied Genetic Technologies Corporation, Dicerna Pharmaceuticals, PanOptica Inc., Carisma Therapeutics, and Aro Biotherapeutics.
Mr. Peacock earned a bachelor’s degree in Business Administration from Villanova University and is a certified public accountant.
Dr. Brian Schreiber
Brian Schreiber, M.D. has served as a member of the Windtree Board of Directors since 2018 and also serves as a member of the Compensation and Nomination and Governance Committee’s. Dr. Schreiber is a Board-Certified Nephrologist and Internist with extensive industry and clinical experience, specializing in rare diseases. Dr. Schreiber is currently the Chief Medical Officer for Cerium Pharmaceuticals, a company who leverages the basic drug discovery work performed by others and moves drug candidates through the clinical and regulatory development processes. In 2015, Dr. Schreiber was also President and Managing Partner for Metabolism Disease Consultants, focusing on drug development, clinical trial design and in-licensing clinical guidance.
Dr. Schreiber also served as Vice President of Medical Development at Relypsa and spent 14 years at Sigma-Tau Pharmaceuticals as the head of its Medical Affairs Department. Dr. Schreiber’s clinical experience includes his role as Chief Medical Director of Dialysis Care Inc., a multi-center dialysis chain providing services in the Northeast and Central Wisconsin and Chairman of Nephrology at LaSalle Clinic, Affinity Medical System, serving as its first president until 2001.
Dr. Schreiber has also continued his activities in academia as Assistant Clinical Professor of Medicine, Department of Medicine, Division of Nephrology, Medical College of Wisconsin since 2001, and has published numerous academic papers, given a variety of lectures, and ran various symposia.